pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
367
stories
Sep 17, 26
Definium’s new psychedelics data, and a reprieve for international scientists
stat
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Sep 17, 26
After Novartis’ devastating M&A losses, long live the executive willing to try
biospace
Sep 17, 26
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
biospace
Sep 16, 26
Novartis to pay $125M for blood-brain barrier crossing platform
biopharma dive
Sep 16, 26
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
Sep 16, 26
Novartis' TREM2 drug fails Phase 2 ALS trial
endpoints
Sep 16, 26
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
Sep 16, 26
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
biospace
Sep 16, 26
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
Sep 16, 26
Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
fiercebiotech
Sep 15, 26
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
Sep 15, 26
FDA approves first radioligand generic, setting up rivalry with Novartis
endpoints
Sep 15, 26
STAT+: Obesity drugmakers are testing in kids as young as 6
stat
Sep 15, 26
STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more
stat
Sep 15, 26
STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
stat
Sep 15, 26
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
Sep 14, 26
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
Sep 14, 26
STAT+: GSK touts lung cancer data from two drugs
stat
Sep 14, 26
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
stat
Sep 14, 26
Scholar Rock SMA drug approved by FDA
biopharma dive
Sep 14, 26
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
Sep 14, 26
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
biospace
Sep 14, 26
STAT+: Definium’s LSD therapy eased anxiety in second large trial
stat
Sep 13, 26
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
stat
Sep 13, 26
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg
fiercebiotech
Sep 12, 26
Setbacks for Novartis; Anthropic looks for a dealmaker; and more
endpoints
Sep 11, 26
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
stat
Sep 11, 26
STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
stat
← prev
page 5 of 13
next →
